期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Met:有望成为治疗三阴型乳腺癌的新靶点 被引量：1

Met:A Promising Anticancer Therapeutic Target for Triple-Negative Breast Cancer
原文传递
导出
摘要 1999年,美国国立癌症研究所提出＂肿瘤分子分型＂,近年来,根据不同的基因表型,乳腺癌被分为6个亚型：Luminal A型、Luminal B型、人表皮生长因子受体-2（Her-2）过表达型、Basal-like型、Normal-like型和Clandin-low型[1]。2005年,Brenton等[2]提出三阴型乳腺癌（triplenegative breast cancer,TNBC）的概念,即雌激素受体（ER）、孕激素受体（PR）和Her-2均为阴性的一种特殊类型乳腺癌。
作者 吴小虎 代文杰
机构地区 哈尔滨医科大学附属第一医院乳腺甲状腺外科
出处 《中国普外基础与临床杂志》 CAS 2013年第7期812-814,共3页 Chinese Journal of Bases and Clinics In General Surgery
关键词 三阴型乳腺癌 靶向治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Prat A,Parker JS,Karginnova O,et al. Phenotypic and molecu-lar characterization of theclaudin-low intrinsic subtype of breastcancer [J]. Breast Cancer Res, 2010, 12(5): R68.
  • 2Brenton JD,Carey LA,Ahmed AA,et al. Molecular classifica-tion and molecular forecasting of breast cancer : ready for clinicalapplication. [J]. JClinOncol, 2005, 23(29): 7350-7360.
  • 3Weigelt B, Baehner FL,Reis-Filho JS. The contribution of geneexpression profiling to breast cancer classification, prognostica-tion and prediction: a retrospective of the last decate [J]. JPathol, 2010, 220(2): 263-280.
  • 4Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvanttherapy and long-term survival in patients with triple-negativebreast cancer [J]. JClin Oncol, 2008,26(8): 1275-1281.
  • 5Dent R,Trudeau M, Pritchard KI, et al. Triple-negative breastcancer: clinical features and patterns of recurrence [J]. ClinCancer Res, 2007,13(15 Pt 1): 4429-4434.
  • 6Ponzo MG, Lesurf R, Petkiewicz S, et al. Met induces mam-mary tumors with diverse histologies and is associated with pooroutcome and human basal breast cancer [J]. Proc Natl Acad SciUSA, 2009,106(31): 12903-12908.
  • 7Gonzalez-Angulo AM, Chen H, Karuturi MS, et al. Frequencyof mesenchymal-epithelial transition factor gene (MET) and thecatalytic subunit of phosphoinositide-3-kinase (PIK3CA) copynumber elevation and correlation with outcome in patients withearly stage breast cancer [J]. Cancer, 2013, 19(1): 7-15.
  • 8Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonalselection of MET amplification in EGFR mutant NSCLC [ J].Cancer Cell, 2010, 17(1): 77-88.
  • 9Baselga J, Albanell J, Ruiz A,et al. Phase H and tumor pharma-codynamic study of gefitinib in patients with advanced breast cancer[J]. JClin Oncol, 2005, 23(23): 5323-5333.
  • 10Mueller KL, Madden JM, Zoratti GL, et al. Fibroblast-secretedhepatocyte growth factor mediates epidermal growth factor Teceptortyrosine kinase inhibitor resistance in triple-negative breast cancersthrough paracrine activation of Met [J]. Breast Cancer Res, 2012,14(4): R104.

同被引文献4

引证文献1

中国普外基础与临床杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部